Overview
Raptor Pharmaceutical Corp. focuses on improving drug targeting to expand the reach and benefit of existing therapeutics into underserved patient populations.
DR Cysteamine for Cystinosis
Raptor's DR Cysteamine is an investigational, delayed-release (DR) oral formulation of cysteamine bitartrate for the potential treatment of nephropathic cystinosis (cystinosis), a rare lysosomal storage disease. Our DR formulation may require less frequent dosing and reduce gastrointestinal side effects. Learn more about our cystinosis research.
